Cytek Biosciences Inc (CTKB)
Return on total capital
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | -21,110 | -16,172 | -7,253 | -1,821 | 3,833 | -32 | -15 | 4,439 | |||
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 393,064 | 415,524 | 424,179 | 423,460 | 425,546 | 416,509 | 411,129 | 407,442 | 405,385 | 403,195 | -10,985 |
| Return on total capital | -5.37% | -3.89% | -1.71% | -0.43% | 0.90% | -0.01% | -0.00% | 1.09% |
December 31, 2023 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-21,110K ÷ ($—K + $393,064K)
= -5.37%
Cytek Biosciences Inc's return on total capital has shown a declining trend over the past few quarters. The company experienced a negative return on total capital in the most recent quarter, indicating that it was not effectively generating returns from its total invested capital. This negative trend suggests that the company may be facing challenges in efficiently utilizing its capital to generate profits. It is important for Cytek Biosciences Inc to closely monitor and address the factors contributing to this decline in order to improve financial performance and enhance shareholder value.
Peer comparison
Dec 31, 2023